Nicotinamide riboside

Nicotinamide Riboside (NR)

1. Identity, Chemical Nature, and Common Forms

Nicotinamide riboside (chemical name: nicotinamide-β-D-ribofuranoside; CAS Number 1341-23-7) is a precursor of nicotinamide adenine dinucleotide (NAD+/NADH) and nicotinamide adenine dinucleotide phosphate (NADP+/NADPH). It is classified as a pyridine-nucleoside and a form of vitamin B3. Structurally, NR is a pyridine nucleoside consisting of an amine (nicotinamide) with a beta-N-glycosidic bond to a ribose. It functions as a precursor to nicotinamide adenine dinucleotide (NAD+) through a two-step and a three-step pathway. The molecular weight of nicotinamide riboside is 255.25 g/mol.

While nicotinic acid and nicotinamide are long-standing vitamin B3 supplements known to restore depleted NAD+ levels, it was only recently that NR and its phosphorylated form, nicotinamide mononucleotide (NMN), became orally available as nutraceutical precursors of NAD+. This followed the identification of the biosynthetic pathways which use these ribosylated building blocks for the efficient synthesis of NAD+ in humans.

In commerce and research settings, NR is most commonly encountered as nicotinamide riboside chloride (the crystalline chloride salt). A crystalline form of nicotinamide riboside chloride has been described to have advantageous properties relative to amorphous forms, since it may be better purified; the crystalline chloride salt is obtained from an amorphous chloride salt by recrystallization in a polar solvent such as methanol. NR is also commercially produced and sold under brand names including NIAGEN® (ChromaDex) and as a component in combination products. Nicotinamide riboside may be used in pharmaceutical compositions, nutritional supplements, or as an intermediate product in the chemical synthesis of NAD(H) or NADP(H).

2. Natural Sources and Occurrence in Food

Nicotinamide riboside was discovered as a nutrient in milk, suggesting that nicotinamide riboside is a useful compound for elevation of NAD+ levels in humans. NR is also naturally found in human breast milk. Beyond dairy, NR is present in other foods at trace concentrations, but the quantities found in any food source are very small relative to supplemental doses used in clinical studies.

The principal naturally occurring dietary sources documented in the scientific literature include:

• Cow's milk: Cow's milk is a source of nicotinamide riboside, with concentrations from 1.6 to 3.2 mg/L.
• Brewer's yeast: Brewer's yeast, commonly used in beer and bread, contains nicotinamide riboside with concentrations ranging from 1.5 to 4.5 mg/g.
• Whey protein: Whey protein, a byproduct of cheese production, contains small amounts of nicotinamide riboside, with concentrations ranging from 0.1 to 0.5 mg/g.

Detection of NR in foods requires nuclear magnetic resonance and mass spectrometry, which is why quantitative data on nicotinamide riboside in food is scarce — it is very difficult to detect. The total dietary intake of NR from food is exceedingly small compared to supplemental doses. Studies of NAD+ precursor metabolism in yeast (Saccharomyces cerevisiae) have provided important scientific models for understanding aging processes, but the measurements of NR in yeast have not been comprehensively studied.

3. Historical and Traditional Context

Unlike many botanical dietary supplements with centuries of documented traditional use, nicotinamide riboside does not have a history of deliberate traditional or ethnobotanical use. Its identity as a distinct molecular entity was not established until the twentieth century.

Nicotinic acid and nicotinamide were defined as the vitamin precursors of NAD+ in Elvehjem's classic discoveries of the 1930s. NAD+ is essential for life in all organisms, both as a coenzyme for oxidoreductases and as a source of ADPribosyl groups used in various reactions, including those that retard aging in experimental systems.

In bacteria, NR was first described in 1944 as a necessary growth factor for the culture of Haemophilus influenzae. H. influenzae was identified as requiring both X factor (hemin) and V factor (NAD) to grow. V factor, purified from blood, was shown to exist in three forms: nicotinamide adenine dinucleotide (NAD), NMN, and NR. NR was the compound that led to the most rapid growth of the H. influenzae bacterium. H. influenzae cannot grow on nicotinic acid (NA), nicotinamide (NAM), or amino acids such as tryptophan (Trp) or aspartic acid (Asp), which were the previously known precursors of NAD.

The identification of nicotinamide riboside as an NAD+ precursor in eukaryotes developed out of the study of pellagra. The accepted view of eukaryotic NAD+ biosynthesis — that all anabolism flows through nicotinic acid mononucleotide — was challenged experimentally, revealing that nicotinamide riboside is an unanticipated NAD+ precursor in yeast. This discovery was published in 2004. In 2004, Dr. Charles Brenner, then at Dartmouth College, reported NR as a previously unappreciated vitamin precursor of NAD+ in humans. Interest in NR as a supplement subsequently grew from this body of research, with its commercial availability emerging in the 2010s. There is no record of NR being used in any traditional medicine system as a recognized, named substance prior to its modern molecular characterization.

4. Biochemistry: Key Constituents and Mechanisms of Action

4.1 NAD+ and Its Central Role

NAD+ is a vital molecule that takes part as a redox cofactor in several metabolic reactions, besides being used as a substrate in important cellular signaling in regulation pathways for energetic, genotoxic, and infectious stress. The redox couples — NAD+ and NADH, and NADP+ and NADPH — play an important role in redox reactions in which NAD and NADP serve as electron carriers. NAD+ also serves as a cofactor/cosubstrate for sirtuins, PARPs, CD38, and other proteins in many signaling pathways, and is the only nicotinamide-derived cofactor that is directly consumed with the concomitant release of nicotinamide and signaling molecules during these reactions.

During the process of aging and in several disease models, the demand on the NAD+ pool far exceeds its availability. NAD+ levels have been reported to decline in response to DNA damage, alcohol metabolism, and aging; and the expression of nicotinamide phosphoribosyltransferase (NAMPT), the enzyme required for NAM salvage, declines with aging and chronic inflammation.

4.2 Biosynthetic Pathways: How NR Enters the NAD+ Pool

Classic NAD+ synthesis pathways characterized in eukaryotes include an eight-step de novo pathway from tryptophan and two pathways using the NAD+ precursors nicotinic acid (NA) and nicotinamide (NAM): a three-step NA-based pathway known as the Preiss-Handler pathway; and an NAM-based pathway involving the enzyme nicotinamide phosphoribosyltransferase (NAMPT) and the formation of nicotinamide mononucleotide (NMN).

Nicotinamide riboside kinases from yeast and humans essential for the NR pathway were identified and found to be highly specific for phosphorylation of nicotinamide riboside. Human neurons require nicotinamide phosphoribosyltransferase (NAMPT) to maintain the NAD+ pool and utilize NRK1 to synthesize NAD+ from NAD+ precursors. Once phosphorylated to NMN by nicotinamide riboside kinases (NRK1/2), NMN is then converted to NAD+ by NMN adenylyltransferases (NMNAT1-3).

Current data suggest that nicotinamide riboside may be the only vitamin precursor that supports neuronal NAD+ synthesis.

4.3 NAD+-Consuming Enzymes: Why NAD+ Declines

The decline in NAD+ occurs due to its consumption by enzymes such as poly(ADP-ribose) polymerase (PARP), NADase (CD38/CD157), NAD+-dependent acetylase (sirtuins), tankyrase (TNKS), and bone marrow stromal cell antigen 1 (BST1).

CD38 uses NAD+ to produce and hydrolyze the Ca2+-mobilizing second messenger cyclic ADP-ribose. CD38 can also degrade the NAD+ intermediates NR and NMN, which further decreases the content of NAD+. The effect of CD38 on NAD+ content was demonstrated in CD38-deficient mice, whose NAD+ levels remain high, preserving mitochondrial respiration and metabolic function with age.

Restoring NAD+ levels allows for an increase in SIRT1 activity due to increased substrate availability, resulting in the inhibition of age-promoting pathways and activation of adaptive and protective transcription factors and processes. The central lineage may be described as the CD38/NAD+/SIRT1 axis, and targeting this axis with nutraceutical interventions may prevent the age-related decline of NAD+ levels.

4.4 Sirtuin Activation

Evidence from cell-based and animal studies indicates that the increase in NAD+ after NR administration stimulates the activity of mammalian sirtuins, supporting the role of sirtuins as a family of proteins whose basal activity can be largely modulated by NAD+ availability. Importantly, the activity of both SIRT1 and SIRT3 are positively regulated by NR both in vitro and in vivo, suggesting that the increase in NAD+ promoted by NR affects, at least, the mitochondrial and the nuclear compartments.

NAD+ is required for the function of sirtuins, a family of enzymes that control gene expression, metabolism, and mitochondrial functions, particularly during changing nutritional conditions. Sirtuins are key target enzymes in healthy aging, such that the search for sirtuin activators has been a major goal of academic, biotechnology, and pharmaceutical research.

Studies in animals and humans have shown that oral NR is superior to nicotinamide, which is better than niacin in terms of the total amount of NAD+ produced at an equivalent dose. NR was also the best of the three in stimulating the activity of sirtuin enzymes.

4.5 NR and PARP Activity

PARP activity and PARP-1 content were not directly affected by NR supplementation in examined models, suggesting that NR increases NAD+ by direct NAD+ biosynthesis rather than by indirectly affecting the major NAD+ salvage (Nampt) or consumption (PARPs) pathways. However, the resulting elevation of NAD+ has downstream effects on PARP-mediated DNA repair capacity.

5. Scientific Evidence by Area of Use

5.1 NAD+ Elevation: Bioavailability and Pharmacokinetics

The most robustly established effect of oral NR supplementation in humans is its ability to increase whole-blood and tissue NAD+ concentrations in a dose-dependent manner. This has been demonstrated across multiple independent clinical trials.

Key clinical study (Trammell et al. / Brenner et al., 2016 — first formal human pharmacokinetics trial): NAD+ is an important coenzyme that mediates cellular metabolism and defends against stresses due to age and overnutrition. This work demonstrated unique bioavailability of the NAD+ precursor vitamin NR in mice and humans, and showed that NR safely elevates human NAD+.

Key clinical study (Conze et al., 2019 — 8-week RCT, healthy overweight adults): To evaluate the kinetics and dose-dependency of NR oral availability and safety in overweight, but otherwise healthy men and women, an 8-week randomized, double-blind, placebo-controlled clinical trial was conducted. Consumption of 100, 300, and 1000 mg NR dose-dependently and significantly increased whole-blood NAD+ (by approximately 22%, 51%, and 142%) and other NAD+ metabolites within 2 weeks. The increases were maintained throughout the remainder of the study. There were no reports of flushing and no significant differences in adverse events between the NR and placebo-treated groups. NR also did not elevate low-density lipoprotein cholesterol or dysregulate 1-carbon metabolism.

Key clinical study (Dellinger et al., 2017 — 8-week RCT, older adults): NRPT (NR combined with pterostilbene) was evaluated in a randomized, double-blind, and placebo-controlled study in a population of 120 healthy adults between the ages of 60 and 80 years, with three treatment arms: placebo, recommended dose (NRPT 1X), and double dose (NRPT 2X), taken daily for eight weeks. Analysis of NAD+ in whole blood demonstrated that NRPT significantly increased NAD+ in a dose-dependent manner. NAD+ levels increased by approximately 40% in the NRPT 1X group and approximately 90% in the NRPT 2X group after 4 weeks. This significant increase was sustained throughout the entire 8-week trial. NAD+ levels did not increase for the placebo group. No serious adverse events were reported.

Key study (Martens et al., 2018 — crossover trial, middle-aged and older adults): A study published in the journal Nature Communications included 24 lean and healthy men and women aged 55 to 79. Half were given a placebo for six weeks, then took a 500 mg twice-daily dose of nicotinamide riboside (NR) chloride; the other half took NR for the first six weeks, followed by placebo. The researchers found that 1,000 mg daily of NR boosted levels of NAD+ by 60 percent. Participants reported no serious adverse effects.

Evidence strength: The ability of oral NR to dose-dependently and significantly increase blood NAD+ concentrations in healthy humans is well-established across multiple independent, well-designed randomized controlled trials. This is the most consistently replicated finding in the NR clinical literature.

5.2 Cardiovascular Health: Blood Pressure and Arterial Stiffness

NAD+ is a key molecule in energy metabolism and cellular functioning which declines with advancing age and chronic disease. Dietary supplementation with NAD+ precursors, such as nicotinamide riboside, boosts NAD+ bioavailability and may improve cardiovascular health.

Nicotinamide riboside is described as an endogenously occurring precursor of NAD+ and a novel caloric restriction mimetic in humans. A small pilot study demonstrated that chronic supplementation with nicotinamide riboside lowered systolic blood pressure (SBP) and carotid-femoral pulse wave velocity (CFPWV) — a gold-standard measure of aortic stiffness and independent risk factor for cardiovascular diseases — in healthy middle-aged and older adults, with the greatest reductions in SBP observed in a subgroup with baseline SBP in the elevated/stage-1 hypertension range.

NR supplementation may offer vascular benefits, such as improved blood pressure and aortic stiffness, although data specific to its effects on cerebrovascular health in specific patient populations remain sparse. A randomized, controlled trial was designed to investigate the efficacy of 3 months of oral supplementation with nicotinamide riboside for decreasing SBP and arterial stiffness in midlife and older adults with initial above-normal (120–159 mmHg) SBP.

Evidence strength: Preliminary and promising for blood pressure and arterial stiffness in middle-aged and older adults. The initial pilot crossover study showed positive signals, but findings require confirmation in larger, longer randomized controlled trials. Evidence at this stage is early-phase.

5.3 Metabolic Health: Obesity and Insulin Sensitivity

Animal studies suggested a positive role for nicotinamide riboside on insulin sensitivity and hepatic steatosis in models of obesity and type 2 diabetes.

Dollerup et al., 2018 (12-week RCT in obese men): The aim of this study was to test the safety of dietary NR supplementation over a 12-week period and its potential to improve insulin sensitivity and other metabolic parameters in obese, insulin-resistant men. Forty healthy, sedentary men with a BMI >30 kg/m², aged 40–70 years, were randomly assigned to 12 weeks of NR (1000 mg twice daily) or placebo. The study (published in American Journal of Clinical Nutrition) confirmed that NR safely elevated NAD+ in blood, but did not demonstrate significant improvements in insulin sensitivity or other primary metabolic endpoints in this obese population. Preclinical evidence had suggested that the NAD+ precursor NR boosts NAD+ levels and improves diseases associated with mitochondrial dysfunction, though these effects were not confirmed in the human metabolic trial.

Evidence strength: Preclinical evidence is supportive; however, the primary human RCT conducted in obese men did not replicate improvements in insulin sensitivity seen in animal models. Evidence for metabolic benefits in humans remains inconclusive and mixed.

5.4 Skeletal Muscle Health and Physical Performance

Nicotinamide precursors such as NMN and NR have received attention for their potential to improve NAD+ levels and mitigate age-related sarcopenia in preliminary models, though evidence on their effects in older adults remains inconclusive.

A 2025 systematic review and meta-analysis (Prokopidis et al.) searched PubMed, Cochrane Library, Web of Science, and Scopus to identify RCTs comparing NR or NMN versus placebo for measures of sarcopenia including skeletal muscle index, handgrip strength, and gait speed. One open-label (non-randomized) study found that 4 months of NR supplementation at 1 g/day resulted in significant improvements in 6-minute walking distance, abdominal muscle strength, elbow flexion, and reduced liver fat in adults with mitochondrial myopathy. However, this study was a non-randomized, open-label design, requiring further research with a more robust study design; and another study using 250 mg/day did not show any changes in muscle strength or physical performance in older adults with Type 2 diabetes. Benefits derived from nicotinamide precursors on mitochondrial morphology may be more applicable in pathways involved in aerobic capacity rather than anaerobic or physical capacity.

A prior review (Custodero et al., 2020) in Experimental Gerontology surveyed the literature on NR in exercise therapy for older adults and found limited, largely preclinical evidence, concluding that the clinical evidence base was in its early stages.

Evidence strength: Preliminary and inconclusive in humans. Animal and in vitro data are supportive of mitochondrial and muscle benefits; human RCT evidence is sparse, with mixed results across populations and doses. Larger and longer clinical trials are needed.

5.5 Neurodegenerative Disease and Neuroprotection

There is growing evidence that substantially greater rates of NAD+ synthesis may be beneficial to protect against neurological degeneration.

In Parkinson's disease (PD): Research reported that increasing NAD+ via the NAD+ precursor nicotinamide riboside significantly ameliorated mitochondrial function in patient-derived neurons. NR prevented age-related dopaminergic neuronal loss and motor decline in fly models of GBA-PD, suggesting NR as a viable clinical avenue for neuroprotection in PD and other neurodegenerative diseases. A clinical safety trial (NR-SAFE, NCT05344404) was registered to assess the safety of oral NR at 3000 mg daily in Parkinson's disease patients, assessing effects on the NAD+ metabolome in blood and urine and on clinical severity of PD measured by the UPDRS scale. Results from this trial were pending at the time the literature search was conducted.

In Alzheimer's disease: A dose-optimization trial (N-DOSE AD, NCT05617508) was registered to investigate NR in Alzheimer's disease populations. These trials are active or recently completed, and full results have not yet been broadly published in peer-reviewed literature.

Evidence strength: Preclinical (cell and animal model) evidence is promising for neurodegenerative conditions. Human clinical trial evidence is at an early stage, with safety and dose-finding trials underway or recently completed. Efficacy data in humans is not yet established for neurodegeneration.

5.6 Cognitive Function and Long COVID

Long COVID often involves cognitive difficulties, immune dysregulation, and mitochondrial dysfunction. Studies suggest that NAD+ precursors like NR may reduce inflammation and support mitochondrial and neurological function. A double-blind, placebo-controlled clinical trial evaluated the effects of NR at 2000 mg/day on NAD+ and changes in cognitive and long-COVID symptoms.

This was a 24-week, double-blind, placebo-controlled trial conducted at a single center in Boston, USA, between August 2021 and September 2023. Fifty-eight community-dwelling participants with long COVID were randomized 2:1 to the NR-NR group (NR for 20 weeks) or the PBO-NR group (placebo for 10 weeks, followed by NR for 10 weeks). The primary outcome was cognition, assessed using the Everyday Cognition scale (ECog), the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), and the Trail Making Test-B (TMT-B). Researchers tested whether raising NAD+ levels with high-dose NR could help restore energy metabolism and ease long-COVID symptoms.

Evidence strength: This represents an early, single-center trial in a specific condition (long COVID). While the study design was rigorous, the sample size was small and results are preliminary. Further replication is required before conclusions can be drawn.

5.7 Mitochondrial Disease

A non-randomized, open-label study found that 4 months of NR supplementation at 1 g/day resulted in significant improvements in 6-minute walking distance, abdominal muscle strength, elbow flexion, and reduced liver fat in adults with mitochondrial myopathy versus healthy age-matched controls. This finding requires confirmation in a randomized study design.

A trial registered at ClinicalTrials.gov (NCT03789175) investigated NR supplementation on mitochondrial function in Li-Fraumeni syndrome, a hereditary cancer predisposition condition associated with mitochondrial dysfunction. Published human studies demonstrated that NR supplementation increases cellular NAD+ content and can be tolerated up to 2000 mg daily without adverse side effects. A pharmacokinetics study (NCT02689882) of NR with dose escalation up to 1000 mg twice daily increased blood NAD+ concentrations over pretreatment levels in every subject, on average about 2-fold. This study revealed no significant side effects, and the primary prespecified safety data showed no changes in the levels of potassium, glucose, uric acid, creatine kinase, or alanine aminotransferase.

Evidence strength: Preliminary. Open-label data suggest potential benefit in mitochondrial myopathy; controlled trial data in specific mitochondrial conditions are limited.

5.8 Aging Biology and Longevity

In stress conditions, NAD+ biosynthesis and levels decrease while the activity of consuming enzymes rises. Dietary precursors can promote NAD+ biosynthesis and increase intracellular levels, representing a potential strategy for reversing physiological decline and preventing diseases.

Aging is a progressive physiological change in an organism that leads to senescence or a decline in energy production in the mitochondria of the brain, skin, pancreas, skeletal muscle, adipose tissue, and liver in part due to a reduction in NAD+ levels and a failure in the organism's capability to acclimate to metabolic stress.

In animal models, NR has demonstrated notable anti-aging properties. NR allowed mice to resist weight gain on a high-fat diet and to prevent noise-induced hearing loss. However, translation of longevity findings from animals to humans remains unproven. No long-term human clinical trials specifically measuring healthspan or lifespan endpoints have been completed and published.

Evidence strength: Animal and mechanistic evidence is compelling for NAD+ decline as a driver of aging pathophysiology. Human evidence for anti-aging or longevity outcomes is currently absent. The established human effects of NR (elevation of NAD+) are a plausible intermediate endpoint; whether this translates to clinically meaningful aging outcomes in humans is not yet demonstrated.

6. Body Systems and Health Areas Associated with NR Research

• Cardiovascular system: Blood pressure regulation, arterial stiffness, endothelial function, and vascular smooth muscle tone. Preclinical studies suggest that NAD+ supplementation can reverse aging phenotypes in cerebrovascular endothelial cells through mechanisms involving sirtuin 1 activation, mitochondrial rejuvenation, and reduction in oxidative stress.
• Skeletal muscle and physical performance: Mitochondrial biogenesis, oxidative capacity, muscle fiber composition, and age-related sarcopenia.
• Nervous system: Neuronal NAD+ synthesis, dopaminergic neuron survival, cognitive function, and neuroinflammation. Current data suggest that nicotinamide riboside may be the only vitamin precursor that supports neuronal NAD+ synthesis.
• Metabolic system: Insulin sensitivity, hepatic lipid metabolism, glucose homeostasis, and obesity-related metabolic dysregulation.
• DNA integrity and repair: Via PARP-mediated DNA repair pathways and sirtuin-dependent chromatin regulation.
• Immune function: NAD+ directly and indirectly affects many cellular processes, including metabolic pathways, DNA repair, and immune cell activities.
• Mitochondrial function: Oxidative phosphorylation, reactive oxygen species management, and mitophagy.

7. Dosage Forms and Doses Used in Clinical Studies

NR is commercially available primarily as oral capsules or tablets containing nicotinamide riboside chloride. The following dosages are those reported in peer-reviewed clinical studies and registered clinical trials:

• 100 mg, 300 mg, and 1000 mg/day (single daily doses): Used in an 8-week RCT in healthy overweight adults, producing NAD+ increases of approximately 22%, 51%, and 142%, respectively.
• 500 mg twice daily (1000 mg/day total): Used in the Martens et al. (2018) crossover study in adults aged 55–79.
• 1000 mg twice daily (2000 mg/day total): Used in the 12-week Dollerup et al. (2018) RCT in obese men aged 40–70.
• 2000 mg/day: Used in the long-COVID clinical trial at Massachusetts General Hospital (24-week duration).
• Up to 2000 mg/day and up to 1000 mg twice daily: Reported in a dose-escalation pharmacokinetics study (NCT02689882) to be tolerated without adverse side effects, with blood NAD+ concentrations approximately doubled on average.
• 3000 mg/day: The dose being investigated in the NR-SAFE trial in Parkinson's disease (NCT05344404).
• 1 g/day (1000 mg/day): Used over 4 months in a study of adults with mitochondrial myopathy.

No official recommended daily allowance (RDA) or tolerable upper intake limit (UL) has been established by regulatory bodies for NR specifically, although NR is classified as a form of vitamin B3 for which the existing niacin equivalency framework provides some reference context. The data from the Conze et al. (2019) study support the development of a tolerable upper intake limit for NR based on human data.

8. Safety Considerations and Adverse Effects

8.1 General Tolerability Profile

NR is well tolerated even in high doses (1000 mg daily) in humans, with no reported adverse effects after 4–8 weeks of treatment in multiple controlled studies.

In the Conze et al. (2019) 8-week RCT, there were no reports of flushing and no significant differences in adverse events between the NR and placebo-treated groups or between groups at different NR doses. NR also did not elevate low-density lipoprotein cholesterol or dysregulate 1-carbon metabolism. This is notable because flushing is a well-known and clinically significant side effect of nicotinic acid (niacin) at therapeutic doses; NR does not appear to share this side effect profile.

8.2 Reported Adverse Events in Clinical Trials

Adverse events reported across clinical trials have generally been mild to moderate in severity. Previous studies showed that NR is in general well tolerated. In one study's intervention group, six adverse events — mild nausea, moderate fatigue, mild headache, moderate dyspepsia, moderate abdominal discomfort, and moderate diarrhea — were possibly related to NR. All participants reporting adverse events recovered, and no serious adverse events were reported.

In a 12-week randomized, double-blind, single-crossover trial, 14 treatment-emergent adverse events (AEs) were reported in 7 subjects out of 30, all of mild severity. During the NR treatment period, AEs included nausea, flushing, leg cramps, and increased bruising. During the placebo period, AEs included headache, skin rash, flushing, fainting, and drowsiness. Only 2 subjects (less than 10%) dropped out due to these AEs, both of whom were in the placebo period.

Based on clinical trial informed consent documentation, the most common adverse events associated with nicotinamide riboside include mild-to-moderate headache, feelings of warmth, hot flushing sensations, gastrointestinal discomfort, and fatigue.

8.3 Absence of Niacin-Like Flushing

A clinically relevant distinction between NR and the closely related vitamin B3 form nicotinic acid (niacin) is the absence of prostaglandin-mediated skin flushing. Multiple RCTs have specifically documented that NR supplementation does not produce the flushing reaction associated with nicotinic acid. This is mechanistically explained by NR's distinct metabolic pathway that does not involve the GPR109A receptor responsible for niacin-induced flushing.

8.4 Effects on Homocysteine and 1-Carbon Metabolism

NR did not dysregulate 1-carbon metabolism in the Conze et al. (2019) trial. However, the NR-SAFE Parkinson's trial includes as an exploratory objective the assessment of effects of oral NR 3000 mg daily on serum homocysteine levels, suggesting that at very high doses this remains an area of monitoring. This is consistent with the known downstream metabolism of nicotinamide (released from NAD+ catabolism) through methylation pathways, which could theoretically affect homocysteine flux at sufficiently high doses.

8.5 Drug Interactions

Nicotinamide riboside may produce drug interactions. Clinical trial protocols advise informing the study team of any prescription or over-the-counter medications, including other nutritional or herbal supplements. No specific major pharmacokinetic interactions with common medications have been definitively established in published peer-reviewed literature to date; however, given NR's broad effects on cellular NAD+ metabolism and downstream signaling (sirtuins, PARPs, CD38), potential interactions with medications affecting these pathways — such as PARP inhibitors used in oncology — represent a theoretical area of concern that has not been fully characterized in human studies.

8.6 Concerns at Very High Doses

High-level NAD+ precursor administration may exert effects through multiple routes. For example, nicotinamide by itself inhibits poly(ADP-ribose) polymerases (PARPs), which protect genome integrity. Elevation of the NAD+ pool alters cellular energy metabolism. High-level nicotinamide also alters cellular methyl metabolism and affects methylation of DNA and proteins, leading to changes in cellular transcriptome and proteome. Methyl metabolites of nicotinamide, namely methylnicotinamide, are predicted to play roles in certain diseases and conditions. These concerns pertain primarily to very high doses of nicotinamide and have not been specifically reproduced with NR supplementation at doses studied in published RCTs, but they remain mechanistically relevant as the downstream metabolites of NR catabolism include nicotinamide.

8.7 Cancer-Related Considerations

Research cited in news coverage (ScienceDaily, 2022) noted that some imaging studies in animal models raised questions about whether NR supplementation could potentially affect cancer progression in certain contexts. This has been an area of preclinical investigation. As of the literature reviewed, no human evidence has established a causal link between NR supplementation and cancer risk, but the topic remains an active area of preclinical research, particularly given NAD+'s central role in cellular metabolism and DNA repair in cancer cells.

8.8 Lack of Long-Term Safety Data

Published clinical trials of NR have predominantly been 8–12 weeks in duration, with a smaller number extending to 6 months. Long-term safety data in humans (beyond 6 months at therapeutic doses) are not yet available in the peer-reviewed literature. Among the strategies to augment NAD+, supplementation with precursors including nicotinamide riboside represents the most practical and extensively studied approach. Over the past two decades, preclinical research and an increasing number of clinical trials have investigated the therapeutic potential of these precursors in preventing or reversing age-associated decline and pathologies; however, promise and limitations of NAD+ precursor supplementation and future directions require further evaluation.

References

• Bieganowski P & Brenner C (2004). Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes establish a Preiss-Handler independent route to NAD+ in fungi and humans. Cell 117(4):495–502 — PubMed
• Bogan KL & Brenner C (2008). Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu Rev Nutr 28:115–130 — PubMed
• Trammell SAJ et al. (2016). Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications 7:12948
• Dellinger RW et al. (2017). Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study. NPJ Aging Mech Dis 3:17 — PMC
• Conze D, Brenner C, Kruger CL (2019). Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Sci Rep 9:9772 — PMC
• Martens CR et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun 9(1):1286 — PubMed
• Dollerup OL et al. (2018). A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am J Clin Nutr 108(2):343–353 — PubMed
• Gosh D et al. (2018). The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC and Fly Models of Parkinson's Disease. Cell Rep 23(10):2976–2988 — PubMed
• Cantó C et al. (2012). The NAD+ Precursor Nicotinamide Riboside Enhances Oxidative Metabolism and Protects against High-Fat Diet-Induced Obesity. Cell Metab 15(6):838–847 — PMC
• Riekehr WM et al. (2019). Syntheses and chemical properties of β-nicotinamide riboside and its analogues and derivatives. Beilstein J Org Chem — PMC
• Gaspar JM et al. (2023). NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health. Front Nutr — PMC
• Mehmel M, Jovanović N, Spitz U (2020). Nicotinamide Riboside — The Current State of Research and Therapeutic Uses. Nutrients 12(6):1616 — PMC
• Custodero C et al. (2020). Nicotinamide riboside — a missing piece in the puzzle of exercise therapy for older adults? Exp Gerontol 137:110972 — PMC
• Freeberg KA et al. (2022). Nicotinamide Riboside Supplementation for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Midlife and Older Adults. Front Cardiovasc Med 9:881703 — PMC
• Prokopidis K et al. (2025). The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis. J Cachexia Sarcopenia Muscle — PMC
• Long COVID NR RCT (2025). Effects of nicotinamide riboside on NAD+ levels, cognition, and symptom recovery in long-COVID: a randomized controlled trial. eClinicalMedicine — PubMed
• Hwang ES & Song SB (2020). Possible Adverse Effects of High-Dose Nicotinamide: Mechanisms and Safety Assessment. Biomolecules 10(5):687 — PMC
• Vreones M et al. (2023). Potential Synergistic Supplementation of NAD+ Promoting Compounds as a Strategy for Increasing Healthspan. Nutrients — PMC
• NR-SAFE: Safety of High-dose Nicotinamide Riboside (NR) in Parkinson's Disease — ClinicalTrials.gov NCT05344404
• University of Iowa — First human clinical trial for nicotinamide riboside (2016)